Last updated: February 15, 2026
What is NDC 00143-9689?
NDC 00143-9689 refers to Methylprednisolone Sodium Succinate for Injection, 40 mg/mL. It is a corticosteroid used primarily for severe allergic reactions, inflammatory conditions, and as part of cancer treatment protocols.
Market Overview
Market Size and Demand
The corticosteroid injectable market is driven by hospital, outpatient, and emergency departments. The global corticosteroids market was valued at approximately USD 20 billion in 2022, with the injectable segment accounting for roughly 20% of total sales. Specific demand for methylprednisolone injectable formulations has grown annually at 4-6% due to increased COVID-19 related hospitalizations and neurological treatments.
Key Market Players
Major manufacturers include:
- Pfizer (brand: Medrol, Solu-Medrol)
- Sagent Pharmaceuticals (generic formulations)
- Hospira (now part of Pfizer)
- Hikma Pharmaceuticals
Distribution Channels
Hospitals and clinics purchase primarily through wholesalers, with government agencies and public health initiatives contributing significantly to sales, especially during the COVID-19 pandemic.
Pricing Landscape
Current Price Range
Wholesale acquisition cost (WAC) for methylprednisolone sodium succinate injectable varies by manufacturer, packaging, and dosage. Typical prices include:
| Package Size |
Average WAC (USD) |
Price Range (USD) |
| 40 mg/mL vials (30 mL) |
$60 |
$55–$70 |
| 40 mg/mL vials (100 mL) |
$150 |
$135–$165 |
| 40 mg/mL vials (50 mL) |
$80 |
$75–$85 |
Pricing Trends
Over recent years, prices for methylprednisolone injections have remained relatively stable, with slight fluctuations due to manufacturing costs and market competition. Generic versions have driven prices down by approximately 10-15% relative to branded products.
Cost Drivers
- Regulatory compliance costs
- Manufacturing scale efficiencies
- Supply chain disruptions
- Hospital procurement policies
Projections and Future Trends
Market Growth
Projected compounded annual growth rate (CAGR) for methylprednisolone injection sales is approximately 3-4% through 2028, influenced by:
- Increased hospitalizations due to respiratory conditions, including COVID-19.
- Expanding use in neurological and autoimmune indications.
- Broader adoption in outpatient settings.
Pricing Forecast
The average WAC is expected to slightly decline (~2-3%) over the next five years because of intensifying generic competition. However, inflation and raw material costs could offset this trend, maintaining prices within a stable range.
Regulatory and Policy Impact
Potential FDA policy changes emphasizing biosimilar and generic competition could further compress prices. Price caps or reimbursement adjustments by CMS could also influence market dynamics.
Risks and Uncertainties
- Supply chain issues stemming from raw material shortages.
- Entry of new biosimilars or generics.
- Changes in clinical guidelines affecting prescribing patterns.
- Economic factors influencing hospital budgets and procurement.
Key Takeaways
- NDC 00143-9689 (methylprednisolone sodium succinate 40 mg/mL) operates in a stable but moderately growing injectable corticosteroid market.
- Current wholesale prices range from approximately $55 to $165 depending on package size.
- Market demand is expected to increase modestly at 3-4% annually through 2028.
- Price projections suggest slight reductions due to increased competition, with stability driven by demand growth.
- External factors such as regulation, supply chain stability, and competitive entries remain key risks.
FAQs
1. How does generic competition affect the price of NDC 00143-9689?
Generic entries typically reduce prices by 10-15% relative to branded products, influencing overall market traction and accessibility.
2. What are the main markets for this drug?
Hospitals and outpatient clinics in the U.S. account for the majority of sales, with a growing presence in international markets, especially in Europe and emerging economies.
3. Are biosimilars expected to impact pricing in the near future?
While biosimilars are more common with monoclonal antibodies, the entry of similar corticosteroid formulations could pressure prices further if approved.
4. How do COVID-19 treatments influence demand?
COVID-19 hospitalizations increased corticosteroid use, including methylprednisolone injections, temporarily boosting demand and stockpiling.
5. What regulatory changes could impact market dynamics?
FDA initiatives promoting biosimilar and generic drug use could accelerate price reductions and market penetration for comparable formulations.
Sources
[1] Market data and trends from IQVIA, 2022.
[2] Industry reports on corticosteroid injections, GlobalData, 2022.
[3] FDA product information and regulatory policies, 2023.
[4] Price analysis from Red Book, 2023.
